MUMBAI, June 9: Shares of drug firm Lupin fell over 2 per cent today after the company recalled more than 54,000 vials of anti-bacterial injection Ceftriaxone manufactured at its Mandideep facility in Madhya Pradesh due to violation of current good manufacturing norms.
After a weak opening, the stock slipped further to trade 2.27 per cent lower at Rs 1,398 on BSE.
On NSE, it went down by 2.33 per cent to Rs 1,397.40.
The ongoing voluntary recall is a class III recall and is for the US and Puerto Rico, according to the latest enforcement report on the USFDA site.
The recall is being initiated by the company’s US arm Lupin Pharmaceuticals Inc covering 54,472 vials of Ceftriaxone injection in various strengths, it added.
Citing reasons for the recall, the USFDA said “finished products manufactured (at Lupin Ltd’s Mandideep plant were) using active pharmaceutical ingredients whose intermediates failed specifications”.
The injection is used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (PTI)
Trending Now
E-Paper
Follow our WhatsApp channel